Loading
A phase 2 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Klus Pharma Inc., active and no longer recruiting.
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) is a phase 2 interventional study registered as NCT05816252 by Klus Pharma Inc., with 356 participants enrolled, started 2023-04-19 and due to reach its primary completion in 2026-06-30. Interventions recorded: SKB264, Pembrolizumab, Carboplatin, Osimertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Osimertinib, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Osimertinib, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Pembrolizumab.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Osimertinib, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Pembrolizumab.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Carboplatin, Small-cell lung cancer.
Shares Sacituzumab tirumotecan, Carboplatin, Small-cell lung cancer, Pembrolizumab.